Clarkfield Care Center | |
805 Fifth Street, Box 458, Clarkfield, Minnesota 56223 | |
(320) 669-7561 | |
Name | Clarkfield Care Center |
---|---|
Location | 805 Fifth Street, Box 458, Clarkfield, Minnesota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 36 |
Occupancy Rate | 72.22% |
Medicare ID (CCN) | 245551 |
Legal Business Name | Clarkfield Care Center |
Ownership Type | Government - City |
NPI Number | 1548291404 |
Organization Name | CLARKFIELD CARE CENTER |
Address | 805 5th St, Clarkfield, MN 56223 |
Phone Number | 320-669-7561 |
News Archive
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.
DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco.
In this story for Kaiser Health News, Bill Scanlon reports: "Just a year ago, as opposition to the proposed health overhaul flared at town hall meetings around the country, President Barack Obama made this western Colorado town of 53,000 people a crucial stop on his tour to revive the stalled initiative" (Scanlon, 8/19).
Noveko International Inc. is pleased to announce that its subsidiary Noveko Inc. has obtained FFP2 classification for its new model of antimicrobial respirators and can now bring them to market in all countries throughout the European Union. These respirators will be marketed as Noveko RD2 antimicrobial respirators.
A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand - thereby blocking cancer cell dissemination and metastasis - and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.
DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco.
In this story for Kaiser Health News, Bill Scanlon reports: "Just a year ago, as opposition to the proposed health overhaul flared at town hall meetings around the country, President Barack Obama made this western Colorado town of 53,000 people a crucial stop on his tour to revive the stalled initiative" (Scanlon, 8/19).
Noveko International Inc. is pleased to announce that its subsidiary Noveko Inc. has obtained FFP2 classification for its new model of antimicrobial respirators and can now bring them to market in all countries throughout the European Union. These respirators will be marketed as Noveko RD2 antimicrobial respirators.
A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand - thereby blocking cancer cell dissemination and metastasis - and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.78 | 14.46 |
Percentage of long-stay residents who lose too much weight | 9.2 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 54.72 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.32 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.19 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 5.75 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.15 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 12.9 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.41 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 7.69 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.3 | 95.98 |
Percentage of short-stay residents who made improvements in function | 84.08 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 71.28 | 82.93 |
News Archive
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.
DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco.
In this story for Kaiser Health News, Bill Scanlon reports: "Just a year ago, as opposition to the proposed health overhaul flared at town hall meetings around the country, President Barack Obama made this western Colorado town of 53,000 people a crucial stop on his tour to revive the stalled initiative" (Scanlon, 8/19).
Noveko International Inc. is pleased to announce that its subsidiary Noveko Inc. has obtained FFP2 classification for its new model of antimicrobial respirators and can now bring them to market in all countries throughout the European Union. These respirators will be marketed as Noveko RD2 antimicrobial respirators.
A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand - thereby blocking cancer cell dissemination and metastasis - and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.
› Verified 7 days ago
Clarkfield Care Center Location: 805 Fifth Street, Box 458, Clarkfield, Minnesota 56223 Phone: (320) 669-7561 |